论文部分内容阅读
肠易激综合征(IBS)是儿童慢性腹痛的常见原因,发病率高,长期可严重影响生活质量。IBS确切发病机制不明,近年发现,肠道微生态失平衡与IBS关系密切,IBS患者肠道微生物定植抗力受损(B/E值降低),肠道微生物总体的多样性和稳定性普遍降低,大肠杆菌和肠球菌属数量增加,双歧杆菌和乳酸杆菌数量减少。IBS无特异性的治疗方法,调节肠道微生态是治疗IBS的重要靶点。益生菌可作为IBS治疗的辅助手段,能否作为主要治疗药物加以推荐尚需更充分的临床证据,确切疗效尚需要开展高质量的临床双盲、随机、对照研究进一步验证,尚无证据表明益生元、合生元、粪菌移植(FMT)可用于治疗IBS。利福昔明治疗IBS可能有效,但需要更多的证据。
Irritable bowel syndrome (IBS) is a common cause of childhood chronic abdominal pain, with a high incidence of long-term can seriously affect the quality of life. The exact pathogenesis of IBS is unknown. In recent years, intestinal imbalance has been found to be closely related to IBS. Impairment of intestinal microbiota colonization in IBS patients (decreased B / E value) and general decline in the diversity and stability of intestinal micro-organisms, Escherichia coli and enterococci increased the number of bifidobacteria and lactobacilli decreased. IBS non-specific treatment, regulation of intestinal microflora is an important target for the treatment of IBS. Probiotics can be used as an adjunct to IBS therapy. Whether it can be recommended as a primary therapeutic agent requires more adequate clinical evidence yet to be validated. High-quality clinical double-blind, randomized, controlled studies need further validation. There is no evidence that probiotics Yuan, synbiotics, fecal bacteria transplantation (FMT) can be used to treat IBS. Rifaximin may be effective in treating IBS, but more evidence is needed.